Integral Diagnostics Ltd. (IDX) AI Stock Analysis

• Market Cap: AU$977.07M
• Dividend Yield: 2.62%
• Average Volume (3M): 911.20K
• Price to Earnings (P/E): 172.4
• Beta (1Y): 0.06
• Revenue Growth: 33.54%
• EPS Growth: N/A
• Country: AU
• Employees: 1,977
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.07
• Shares Outstanding: 372,926,670
• 10 Day Avg. Volume: 1,057,226
• 30 Day Avg. Volume: 911,197
• PEG Ratio: -1.57
• Price to Book (P/B): 1.12
• Price to Sales (P/S): 1.24
• P/FCF Ratio: 55.58
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$3.44
• Price Target Upside: 40.41% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: AU$3.00 ▲(22.45% Upside)

Integral Diagnostics Ltd. has strong revenue growth and operational efficiency, but faces significant challenges in profitability and cash flow management. The technical indicators suggest bearish momentum, and the stock appears overvalued with a high P/E ratio. These factors contribute to a cautious outlook, reflected in the overall score.

Positive Factors

Revenue Growth

Strong revenue growth reflects robust market demand and effective service delivery, positioning the company well for future expansion.

Operational Efficiency

High gross profit margins indicate effective cost management and pricing power, supporting long-term profitability potential.

Improved Leverage

Improved leverage suggests better financial management and reduced risk, enhancing financial stability and flexibility.

Negative Factors

Low Net Profit Margin

Low net profit margins indicate difficulty in converting sales into actual profit, which could hinder sustainable financial growth.

Declining Free Cash Flow

A significant decline in free cash flow raises concerns about liquidity and the ability to fund operations and growth initiatives.

Low Return on Equity

Low return on equity suggests inefficient use of shareholder funds, potentially limiting investor appeal and future capital raising.

Integral Diagnostics Ltd. Business Overview & Revenue Model

Company Description

Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. It provides services through 67 radiology clinics. The company was incorporated in 2008 and is headquartered in Melbourne, Australia.

How the Company Makes Money

Integral Diagnostics generates revenue primarily through the provision of diagnostic imaging services to patients and healthcare professionals. The company's revenue model is based on billing for individual imaging procedures, which are often covered by public and private health insurance schemes. Key revenue streams include payments from health insurers, direct payments from patients, and government funding for specific services. Additionally, IDX benefits from strategic partnerships with hospitals and healthcare providers, which help secure a steady flow of referrals for imaging services. The company also invests in expanding its service offerings and enhancing operational efficiencies to drive profitability.

Integral Diagnostics Ltd. Financial Statement Overview

Summary

Integral Diagnostics Ltd. shows strong revenue growth and operational efficiency, as evidenced by high gross profit margins. However, the company faces challenges in converting this growth into net income, reflected in low net profit margins and return on equity. The balance sheet shows improved leverage, but cash flow concerns persist due to declining free cash flow. Overall, while the company is on a growth trajectory, it needs to focus on enhancing profitability and cash flow management to ensure sustainable financial health.

Income Statement

Integral Diagnostics Ltd. has demonstrated strong revenue growth with a 27.66% increase in the latest year, indicating a robust expansion trajectory. The gross profit margin remains high at 95.52%, showcasing operational efficiency. However, the net profit margin is low at 0.75%, suggesting challenges in translating revenue growth into net income. The EBIT and EBITDA margins are moderate, reflecting stable operational performance but room for improvement in cost management.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.84, indicating a better balance between debt and equity compared to previous years. However, the return on equity is low at 0.67%, pointing to limited profitability for shareholders. The equity ratio is stable, suggesting a solid asset base, but the company needs to enhance its profitability metrics to strengthen its financial position further.

Cash Flow

Operating cash flow remains positive, but the free cash flow has declined significantly by 58.96%, raising concerns about cash generation capabilities. The operating cash flow to net income ratio is moderate, indicating some efficiency in converting income into cash. However, the free cash flow to net income ratio is low, suggesting potential liquidity challenges if the trend continues.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	627.22M	627.22M	469.70M	440.10M	358.74M	348.81M
Gross Profit	163.28M	599.09M	446.78M	97.76M	83.84M	92.19M
EBITDA	96.64M	87.70M	12.10M	92.74M	69.90M	88.94M
Net Income	4.67M	4.67M	-60.70M	25.04M	14.60M	31.27M
Balance Sheet
Total Assets	1.43B	1.43B	744.28M	839.01M	783.01M	654.90M
Cash, Cash Equivalents and Short-Term Investments	52.10M	52.10M	42.44M	33.85M	123.19M	62.20M
Total Debt	585.01M	585.01M	355.59M	365.08M	340.99M	308.36M
Total Liabilities	732.53M	732.53M	442.57M	465.96M	435.77M	400.16M
Stockholders Equity	693.00M	693.00M	301.71M	373.05M	347.24M	254.74M
Cash Flow
Free Cash Flow	14.01M	14.01M	42.28M	27.42M	9.33M	49.30M
Operating Cash Flow	73.77M	73.77M	66.16M	71.42M	37.10M	69.57M
Investing Cash Flow	-64.99M	-64.99M	-27.90M	-128.96M	-55.69M	-56.66M
Financing Cash Flow	710.00K	710.00K	-29.45M	-31.85M	81.13M	-7.83M

Integral Diagnostics Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDX, the sentiment is Negative. The current price of 2.45 is below the 20-day moving average (MA) of 2.54, below the 50-day MA of 2.58, and below the 200-day MA of 2.52, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 39.26 is Neutral, neither overbought nor oversold. The STOCH value of 20.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IDX.

Integral Diagnostics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACL	71 Outperform	AU$524.72M	15.63	18.59%	4.43%	6.73%	37.16%
MVF	67 Neutral	AU$268.85M	10.75	10.25%	6.14%	6.65%	―
SHL	64 Neutral	AU$10.27B	19.43	6.32%	4.65%	9.44%	-0.37%
IDX	55 Neutral	AU$977.07M	172.37	0.94%	2.62%	33.54%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HLS	50 Neutral	€635.37M	-1.21	-67.21%	―	-23.02%	33.11%
GSS	41 Neutral	AU$60.19M	-2.93	-36.16%	―	62.81%	16.37%

Integral Diagnostics Ltd. Corporate Events

Integral Diagnostics Appoints New CEO to Drive Growth and Innovation

Integral Diagnostics (IDX) has appointed Jason Martinez as its new Managing Director and Chief Executive Officer, succeeding Dr. Ian Kadish, who will retire at the end of FY26. Martinez, who brings over 20 years of experience in the diagnostic imaging and health sectors, is expected to drive growth through organic means and mergers and acquisitions, leveraging AI capabilities and focusing on margin improvement. His appointment is seen as a strategic move to continue delivering excellent patient care and improving returns for investors, positioning IDX as a leading force in the diagnostic imaging industry.

Integral Diagnostics Secures Strong Shareholder Support at AGM

Integral Diagnostics Limited announced that all resolutions at its Annual General Meeting were passed, reflecting strong shareholder support. The successful resolutions, including the election of directors and approval of financial assistance, indicate stability and continued confidence in the company’s strategic direction.

Integral Diagnostics Reports Strong FY25 Performance and Strategic Growth

Integral Diagnostics Ltd. has reported strong financial performance for FY25, driven by its successful merger with Capitol Health, which has exceeded synergy expectations. The company is well-positioned for further growth due to industry tailwinds and strategic initiatives in sustainability, including a focus on environmental, social, and governance responsibilities. IDX’s increased scale and improved margins position it to capitalize on future M&A opportunities and industry consolidation.

Integral Diagnostics to Release Shares from Escrow

Integral Diagnostics Limited announced the release of 876,068 fully paid ordinary shares from voluntary escrow on November 1, 2025. This release will not affect the company’s issued capital, indicating a stable financial position and potentially reassuring stakeholders about the company’s operational consistency.

Integral Diagnostics Issues New Performance Rights

Integral Diagnostics Ltd. announced the issuance of 677 performance rights under an employee incentive scheme. These unquoted securities are subject to transfer restrictions and are not listed on the ASX, indicating a strategic move to incentivize employees and align their interests with company performance.

Integral Diagnostics Issues New Performance Rights

Integral Diagnostics Ltd. announced the issuance of 214,921 performance rights under an employee incentive scheme. These unquoted securities are subject to transfer restrictions and are not listed on the ASX until these restrictions are lifted, potentially impacting employee retention and motivation.

Integral Diagnostics Issues New Performance Rights Under Incentive Scheme

Integral Diagnostics Ltd. announced the issuance of 829,926 performance rights under an employee incentive scheme. These unquoted securities are subject to transfer restrictions and are not listed on the ASX until the restrictions are lifted, potentially impacting employee retention and motivation strategies.

Integral Diagnostics Ltd. Announces Quotation of New Securities

Integral Diagnostics Ltd. has announced the application for quotation of 299,862 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of a dividend or distribution plan, potentially impacting the company’s financial structure and market presence by increasing its available capital and shareholder base.

Integral Diagnostics Announces 2025 Annual General Meeting Details

Integral Diagnostics Ltd. has announced its 2025 Annual General Meeting scheduled for 31 October 2025, allowing shareholders to participate either in person or online. This meeting is a significant event for the company as it provides an opportunity for stakeholders to engage with the company’s leadership and discuss future strategies, potentially impacting its operations and market positioning.

Integral Diagnostics Unveils 2025 Sustainability Report

Integral Diagnostics Ltd. has released its 2025 Sustainability Report, emphasizing its commitment to delivering sustainable value to stakeholders, embracing change, and prioritizing patient care. The report highlights the company’s dedication to medical leadership and integrity, as well as its vision for a healthier world. It also acknowledges the Traditional Owners of Country throughout Australia, reflecting its respect for Aboriginal and Torres Strait Islander peoples.

Integral Diagnostics Updates Dividend Distribution Details

Integral Diagnostics Ltd. has updated its previous announcement regarding the dividend distribution for the period ending June 30, 2025. The update includes details on the exchange rate used for converting the Australian Dollar-denominated dividend into New Zealand Dollars and the Dividend Reinvestment Plan (DRP) share price. This announcement is significant as it provides clarity on the financial aspects of the dividend distribution, potentially impacting shareholders’ decisions and the company’s financial strategy.